prurigo nodularis
prurigo nodularis
Explore linked clinical trials. Standard reference: MONDO:002604512 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults | prurigo nodularis | Recruiting | Not stated | 2026-09-09 | NCT06988618 | |
| Determinants of Chronic Inflammatory Skin Disease Trajectories | Bacterial Infections and Mycoses, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Infections, Lichenoid Eruptions, Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Suppuration, alopecia, alopecia areata, atopic eczema, bacterial infectious disease, dermatitis, disorder of pilosebaceous unit, hereditary disease, hereditary skin disorder, hidradenitis, hidradenitis suppurativa, hypopigmentation of the skin, hypotrichosis, immune system disorder, lichen planus, prurigo nodularis, psoriasis, rosacea, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, skin pigmentation disorder, sweat gland disorder, vitiligo | Recruiting | Not stated | 2026-08-28 | NCT05928169 | |
| Efficacy of Topical Cannabidiol for Eczema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, prurigo nodularis, skin disorder | Enrolling by invitation | Phase 2 | 2026-08-04 | NCT06994520 | |
| A Study of Barzolvolimab in Patients With Prurigo Nodularis | prurigo nodularis | Active, not recruiting | Phase 2 | 2026-08-04 | NCT06366750 | |
| A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine | prurigo nodularis | Active, not recruiting | Not stated | 2026-07-31 | NCT06087627 | |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | prurigo nodularis | Active, not recruiting | Phase 3 | 2026-05-28 | NCT06516952 | |
| Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis | prurigo nodularis | Recruiting | Phase 2 / Phase 3 | 2026-04-29 | NCT06554509 | |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) | prurigo nodularis | Active, not recruiting | Phase 3 | 2026-04-14 | NCT06516965 | |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis | prurigo nodularis | Recruiting | Phase 3 | 2026-01-15 | NCT06293053 | |
| A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) | prurigo nodularis | Active, not recruiting | Phase 3 | 2025-11-12 | NCT04204616 | |
| Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis | prurigo nodularis | Recruiting | Phase 3 | 2025-04-18 | NCT06779136 | |
| China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project | prurigo nodularis | Recruiting | Not stated | 2024-08-15 | NCT05316805 |